AI Article Synopsis
- - The study tested the abuse potential of Ro 64-6198, an agonist for the orphanin FQ (OFQ) receptor known for its anxiety-reducing effects, using a rat model to measure conditioned place preference (CPP).
- - Unlike morphine, which showed significant rewarding effects, neither Ro 64-6198 nor the anti-anxiety drug alprazolam produced preference or aversion, indicating low potential for abuse.
- - The findings suggest that Ro 64-6198 may be a safer alternative in anxiolytic treatments, as it does not carry the same risk of non-medical use or dependence as traditional opioids.
Article Abstract
The abuse liability of Ro 64-6198, an orphanin FQ (OFQ) receptor full agonist that exhibits anxiolytic properties, was evaluated using an unbiased conditioned place preference (CPP) paradigm in rats. As OFQ is structurally related to opioid peptides and also exhibits anxiolytic-like properties, the effect of Ro 64-6198 on CPP was compared with those of morphine and alprazolam. We show here that neither Ro 64-6198 nor alprazolam exhibited rewarding or aversive properties, whereas morphine induced a pronounced CPP. These results strengthen the previous finding that Ro 64-6198 lacked abuse liability in a self-stimulation paradigm, suggesting that this new class of anxiolytic drugs is devoid of the risk for potential non-medical use and dependence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00001756-200203250-00018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction.
Proc Natl Acad Sci U S A
January 2025
Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405.
Dysregulation of GABAergic inhibition is associated with pathological pain. Consequently, enhancement of GABAergic transmission represents a potential analgesic strategy. However, therapeutic potential of current GABA agonists and modulators is limited by unwanted side effects.
View Article and Find Full Text PDFAlcohol Use Disorder Polygenic Score Compared With Family History and ADH1B.
JAMA Netw Open
December 2024
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis.
Importance: Identification of individuals at high risk of alcohol use disorder (AUD) and subsequent application of prevention and intervention programs has been reported to decrease the incidence of AUD. The polygenic score (PGS), which measures an individual's genetic liability to a disease, can potentially be used to evaluate AUD risk.
Objective: To assess the estimability and generalizability of the PGS, compared with family history and ADH1B, in evaluating the risk of AUD among populations of European ancestry.
Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review.
Am J Sports Med
January 2025
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Background: Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their performance-enhancing implications, SARMs are increasingly abused by athletes. To date, SARMs have no Food and Drug Administration approved use, and recent case reports associate the use of SARMs with deleterious effects such as drug-induced liver injury, myocarditis, and tendon rupture.
View Article and Find Full Text PDFThe Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors.
CNS Drugs
January 2025
Cognitive and Clinical Neuroimaging Core, McLean Hospital, McLean Imaging Center, Belmont, MA, USA.
The relationship between cannabis use and mental health is complex, as studies often report seemingly contradictory findings regarding whether cannabis use results in more positive or negative treatment outcomes. With an increasing number of individuals using cannabis for both recreational (i.e.
View Article and Find Full Text PDFPsychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research.
Am J Psychiatry
January 2025
Department of Psychiatry (McIntyre, Mansur, Rosenblat) and Department of Pharmacology and Toxicology (McIntyre, Mansur, Rosenblat), University of Toronto, Toronto; Brain and Cognition Discovery Foundation, Toronto (Kwan, Teopiz); Faculty of Medicine, University of Ottawa, Ottawa (Kwan); Champalimaud Research and Clinical Center, Champalimaud Foundation, Lisbon (Oliveira-Maia); NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisbon (Oliveira-Maia); Department of Psychiatry and Behavioral Sciences, University of South Carolina School of Medicine, Greenville (Maletic); Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (Suppes); Department of Psychiatry, University of California, San Diego (Stahl).
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Preliminary evidence also supports efficacy in other psychiatric disorders (e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!